Surely LTers would have demonstrated that they're comfortable with the level of risk you speak of. Most of us here were around in 2020 where they rode it from these levels (19c in June 2020) down to 4c the following year. And many LTers have been around when we've seen far bigger falls.
If anyone doesn't want to risk the drop on a NO vote however, they're better off just selling at current prices. As you're risking a less than 2c gain for an x or even 1x cent loss.
Yes the company will need to do a CR (or accept a cash payment for offering an exclusive license to Pfizer, the CR would be preferable however as with being in a more stable position if they choose to go that route they can negotiate a better deal). The company needed to do a CR before, back at the levels you said they were trading at prior to the scheme. They only avoided doing so because they took a cash injection from Pfizer along with the scheme. The major downside is that the BOD have been too aggressive at shining a negative light on the company as they want the scheme to go through, but they may still be able to repaint it by pushing the acuity report (as that was quite good) or what parties are interested in the covid detection.
As for a NO future, regardless of if Pfizer return and make another offer or stop trying to acquire the company, I'm doubtful they'd walk away from RAP entirely. Most likely they'll still want to work with the company. And beyond that there's numerous things in the pipeline that are of interest such as SleepCheck for clinical use FDA (with low funds they might be best linking up with a distributor for it), ResApp NHS pilot (depending on how that goes that could be a huge catalyst for ResAppDx), etc.
RAP Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
